Related Experiment Video

Updated: Aug 25, 2025

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

8.3K

Targeting Cdc20 for cancer therapy

Seung Min Jeong1, Quyen Thu Bui2, Minseok Kwak3

  • 1Department of Biochemistry, Institute for Aging and Metabolic Diseases, College of Medicine, The Catholic University of Korea, Seoul 06592, Republic of Korea.

Biochimica Et Biophysica Acta. Reviews on Cancer
|October 15, 2022
PubMed

Insights

The Anaphase-Promoting Complex/Cyclosome (APC/C) regulates cell division. Its co-activator Cdc20, an oncogene, is a potential therapeutic target for cancers driven by cell cycle dysregulation.

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Biochemistry

Background:

  • The Anaphase-Promoting Complex/Cyclosome (APC/C) is a crucial E3 ubiquitin ligase regulating cell division.
  • APC/C, with co-activators Cdc20 and Cdh1, controls the degradation of cell cycle regulators.
  • Dysregulation of cell cycle control is linked to uncontrolled proliferation and cancer development.

Purpose of the Study:

  • To review recent findings on the role of APC/C-Cdc20 in cell cycle regulation.
  • To highlight Cdc20's oncogenic properties and its potential as a cancer therapeutic target.

Main Methods:

  • Literature review of recent research on APC/C, Cdc20, and Cdh1.
  • Analysis of the functional roles of APC/C-Cdc20 in cell cycle progression.
  • Summary of findings regarding Cdc20's involvement in tumorigenesis.

Main Results:

  • Cdc20 exhibits oncogenic properties, contrasting with Cdh1's tumor-suppressive role.
  • Strict regulation of Cdc20 expression is essential for proper cell cycle progression.
  • APC/C-Cdc20 plays a critical role in timely and precise cell division.

Conclusions:

  • Cdc20 is an emerging therapeutic target for cancer treatment due to its oncogenic function.
  • Targeting Cdc20 activity may offer beneficial therapeutic interventions for various cancers.
  • Understanding APC/C-Cdc20 regulation is key to developing novel cancer therapies.
Keywords:
CancerCdc20Cell cycleE3 ligasecancer therapy

More Related Videos

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

740
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K